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Summary 
The interaction between activated vascular endothelium and T cells has been shown to play an 
important role in the recruitment and activation of T cells at sites of inflammation.  Here we 
report the expression of CD40 by vascular endothelial cells and its regulation by inflammatory 
agents. Using the soluble recombinant CD40 ligand,  sgp39, we show that the interaction  of 
CD40 with its ligand can lead to endothelial cell activation,  which in turn leads to leukocyte 
adhesion. This adhesion is partly mediated by the expression of E-selectin. In addition to E-selectin 
expression, ~gp39 induces the expression of intercellular adhesion molecule 1 and augments the 
tumor necrosis factor cz-induced expression of vascular cell adhesion molecule 1.  The effects 
of sgp39 on endothelial cells can be blocked with anti-gp39 monoclonal antibody (mAb), anti- 
CD40 mAb, or soluble CD40.  Staining of tissues from healthy human skin using anti-CD40 
mAb showed very weak expression of CD40 by the endothelium, while skin involved in inflam- 
matory disease showed marked upregulation of CD40 expression. These studies suggest that 
interactions between cell surface proteins expressed by activated T cells with their receptors on 
vascular endothelium can stimulate the vasculature at sites of inflammation and may be involved 
in normal inflammatory responses and in inflammatory disease. 
C 
D40,  a 50-kD  glycoprotein  expressed by a range of 
cell types of the immune system, functions as a signaling 
protein. It was initially described and studied on B cells, where 
stimulation  with  anti-CD40  mAb was  shown to  induce 
proliferation and isotype switching in the presence of an ap- 
propriate costimuli. For example, early studies demonstrated 
that anti-CD40 mAbs are synergistic with PMA, anti-CD20 
mAb, or IL-4 for the induction of B cell proliferation (1-4). 
Further studies have shown that anti-CD40 treatment with 
IL-4 as the costimulator results in the secretion of IgE, IgM, 
IgA, and soluble CD23 (4-8). With IL-10 as the costimu- 
lator, anti-CD40 treatment results in the secretion of IgA, 
IgM, and IgG (9, 10). In addition,  anti-CD40 presented by 
CD32-transfected  L cells in combination with IL-10 and TGF-3 
results in the production of IgA from slgD § B cells (9). 
CD40 is also expressed and functional on several other cell 
types.  Monocytes respond to  anti-CD40  or CD40 ligand 
(gp39)  in conjunction with GM-CSF,  IL-3, or IFN-3'  by 
producing cytokines (11). Thymic epithelium has also been 
shown to express CD40,  and stimulation with anti-CD40 
in conjunction with IFN-3, and IL-1 leads to secretion of 
GM-CSF  (12). CD40 is expressed by normal basal epithe- 
lium,  follicular  dendritic cells, and  some carcinoma-  and 
melanoma-derived  cell lines (13-16). More recently, it has 
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been found that T cells express CD40 and respond to gp39 
by the proliferation and expression of cytokines and activa- 
tion markers (17), and dendritic Langerhans cells respond to 
ligation of CD40 by altering their morphology and surface 
molecule and cytokine expression (18). 
The molecular steps leading to the recruitment and activa- 
tion of leukocytes at sites of inflammation are being dissected. 
The current hypothesis is that leukocyte recruitment and ac- 
tivation at sites of inflammation is a sequential multistep pro- 
cess (for review see references 19, 20).  First, adhesion pro- 
teins of the selectin family mediate the rolling of leukocytes 
on the activated vascular endothelial cells. The rolling leuko- 
cytes then probe the endothelial cell surface and come into 
contact with  high local  concentrations  of cytokines  and 
chemokines, which emanate from the site of inflammation 
and are bound and presented by proteoglycans  on the er,- 
dothelial cell surface. These proinflammatory  molecules acti- 
vate the leukocytes, which then become firmly attached to 
the vascular cell wall, a process thought to be primarily medi- 
ated by members of the integrin family of  receptors. The firmly 
bound leukocytes then extravasate  into the surrounding tissue 
and migrate to the site of inflammation. The role of endothelial 
cell surface proteins in this process has been the subject of 
intensive study. For example, expression  of P-selectin (CD62P), 
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1)1; (CD54), and vascular cell adhesion molecule 1 (VCAM-1) 
(CD106) by activated endothelial cells results in leukocyte 
binding to the activated endothelial cells. Furthermore, the 
interaction of molecules such as ICAM-1 and VCAM-1 with 
their corresponding integrin receptors enhances T  cell acti- 
vation. In addition, in the presence of IFN-3',  endothelial 
ceils can express MHC class II,  suggesting that at sites of 
inflammation these ceils  may also  present antigen (21). 
There is evidence that the cell surface proteins expressed 
by some of the activated leukocytes transiently bound to the 
endothelial cells at sites of inflammation provide stimulatory 
signals to the endothelial cells. For example, studies have shown 
that activated T  cells can alter the expression of MHC or 
enhance vascular permeability in a cell contact-dependent 
fashion (22, 23).  Thus,  signals  delivered to the endothelial 
cells by cell surface proteins that are expressed by activated 
leukocytes may play an important role in ensuring an effec- 
tive inflammatory response. These interactions may enhance 
the ability of the endothelial cell to recruit and activate leu- 
kocytes, facilitate the molecular events that lead to leukocyte 
diapedesis,  and/or enhance the ability of the endothelial cells 
to act as APC. 
To investigate if the T cell activation antigen gp39 (CD40L, 
TRAP,  T-BAM) is involved in the stimulation of vascular 
endothelial cells during endothelial cell-T cell interactions at 
a site of inflammation, we examined if vascular endothelial 
cells express CD40, how its expression might be regulated, 
and if ligation of CD40 results in endothelial cell activation. 
Materials  and Methods 
Antibodies and Reagents.  The mAb against CD40 (G28-5, mouse 
IgG1), a gift from J. Ledbetter (Bristol-Myers  Squibb, Seattle, WA), 
has been described previously (1). TNF-ot produced in Escherichia 
coli was purchased from R&D Systems, Inc. (Minneapolis, MN), 
recombinant IL-1B  produced in E. coli, and IFN-y were purchased 
from Genzyme Corp. (Cambridge, MA); LPS, isolated from E, coli 
Ol11:B4 and phenol/water purified, was purchased from Sigma 
Chemical Co. (St. Louis, MO); sgp39, a fusion protein consisting 
of the extracellular domain of murine CD8 (Ly2) and the extracell- 
ular domain of gp39, was produced by transient expression in COS 
cells as previously described (24) and purified by chromatography 
on an anti-Ly2 affinity column, mAb 39-1.106 was a gift from A. 
Siadak (Bristol-Myers Squibb); F(ab')2 fragments were produced 
by digestion of the intact antibody with pepsin (Boehringer Mann- 
heim Corp.,  Indianapolis, IN). The Fc fragment was removed by 
affinity chromatography  using immobilized protein A (IPA-300; 
Repligen Corp.,  Cambridge,  MA). 
Endothelial Cell Culture and Stimulations.  Endothelial cells were 
cultured  and expression assays were performed essentially as de- 
scribed (25). Human umbilical vein endothelial cells (HUVEC) and 
human aortic endothelial cells (HAEC) from C1onetics Corp. (San 
Diego, CA) were cultured and stimulated in medium 199 (GIBCO 
BILL, Gaithersburg,  MD) with additions to final concentrations 
as follows: 4 mM r-glutamine,  48.5 /~g/ml penicillin, 80/~g/ml 
streptomycin, 1 mM sodium pyruvate (Sigma Chemical Co.), 90 
1 Abbreviations used in this paper: HAEC, human aortic endothelial cells; 
HUVEC, human umbilical vein endothelial  cells; ICAM-1, intercellular 
adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1. 
/xg/ml heparin (Sigma Chemical Co.), 30/~g/ml endothelial growth 
supplement  (Collaborative Biomedical Products, Bedford, MA), 
and 20% fetal bovine serum. Endothelial cells were grown in tissue 
culture flasks treated with 1% gelatin and plated at 1.5  x  104 cells 
per well in flat-bottomed 96-well  tissue culture plates (Costar Corp., 
Cambridge, MA) that had been coated with 1/~g fibronectin per 
well (Collaborative Biomedical Products). Endothelial cells were 
stimulated 1-2 d after plating. Cells were used at passage 4 or 5. 
Optimum doses of cytokines, fusion protein, or LPS were deter- 
mined by titration. 
Flow Cytometry.  HUVEC were treated with 0.5 mM EDTA 
in PBS to remove them from the flask and then stained for CD40 
expression by incubating the cells on ice with G28-5 or an isotype- 
matched control at 2.5 #g per well, followed  by a FITC-conjugated 
goat anti-mouse antibody (1:500; Tago, Inc., Burlingame, CA) or 
by incubation with supernatant from COS cells expressing ~gp39 
or sCD72 (100/~1 per well), followed by PE-conjugated anti-Ly2 
(mAb 53-6.7, Boehringer Mannheim Corp.). All antibody incuba- 
tions were performed in RPMI containing 2% fetal bovine serum 
and 0.1% NAN3. Cells were analyzed with a FACScan  |  flow cy- 
tometer (Becton Dickinson  & Co., Mountain  View, CA). 
E-selectin, ICAM-1, VCAM-1, and CD40 Expression Assays.  Stim- 
ulants were added in medium  199 plus additions at 100/zl/well 
and incubated at 37~  for 4 h before assaying for E-selectin expres- 
sion and 24 h before assaying for ICAM-1, VCAM-1, and CD40 
expression. Plates were then washed twice with cold PBS, fixed 
for 10 min with 0.5% glutaraldehyde in PBS at 4~  washed four 
times with 3% goat serum/PBS/20 mM EDTA (blocking buffer), 
and blocked for 1 h at 37~  or overnight at 4~  in the same buffer. 
Cells were treated with 100/zl murine mAbs in blocking buffer 
for 1 h at 37~  at the following concentrations: anti-E- and anti- 
P-selectin (R&D Systems, Inc.) at 0.25/~g/ml, anti-ICAM-1  and 
anti-VCAM-1 (Becton Dickinson  & Co.) at 1/zg/ml, or G28-5 
at 5 #g/ml. Plates were washed four times with blocking buffer, 
incubated 1 h at 37~  with horseradish peroxidase--conjugated  anti- 
mouse IgG in blocking buffer (Jackson ImmunoResearch Labora- 
tories, Inc., West Grove, PA; 100/zl/well,  1:2,000 dilution),  and 
then washed four times. Plates were developed using EIA Chro- 
magen  Reagent  in  EIA-buffered Substrate  (both  from Genetic 
Systems Corp.,  Redmond,  WA; 100/xl per well, 1:100 dilution) 
and stopped with 100/~l/well of 1 N H2504. The absorbance was 
determined at dual wave lengths of 450 and 630 nm. 
PMN/Endothelial  Cell  and  HL-60/Endothelial  Cell  Adhesion 
Assay.  Adhesion  of PMN cells or the premyelocytic  cell line HD60 
to endothelial cells was measured essentially  as previously  described, 
with modifications (26). Briefly, PMN were separated from whole 
blood with Polymorphoprep  TM (Nycomed), resuspended to a den- 
sity of 4  x  106 cells per ml in PBS containing  1 mM each of 
CaC12 and MgClz and 10 mM 2',7'-bis-(2-carboxyethyl)-5 (and- 
6)-carboxyfluorescein,  ace toxy methyl ester (Molecular  Probes, Inc., 
Eugene, OR), and then incubated in the dark for 15 rain at 37~ 
An equal volume of RPMI media was added, and the cells were 
pelleted  and  washed  with  1  mM  CaC12/MgC12 PBS  and 
resuspended at 2.5  x  106 cells per ml. Labeled PMN,  100/~1 per 
well, were added to a monolayer of HUVEC or HAEC that had 
been plated as described above and activated for 4 h. Plates were 
swirled gently at room temperature for 30 rain in the dark, the 
wells were washed two times with PBS, and the adherent neutro- 
phils were lysed by the addition of 100/~1 per well of 1% SDS 
in 50 mM "Iris, pH 8. Fluorescence was measured on a microplate 
fluorescence reader. Assays for the adherence of HL-60 cells were 
performed using the same procedure. 
Patients.  Patients  with allergic contact dermatitis (n  =  5) and 
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(n = 5). None of the patients had received previous treatment for 
their skin condition. After we obtained informed consent, full- 
thickness 4-mm punch biopsies were taken from the lesional skin 
of the patients. In the control group, 4-mm punch biopsies were 
taken from the volar aspects of the forearm. Samples were snap 
frozen immediately and stored at  -80~  until use. 
Immunohistochemistry.  Frozen skin specimens were embedded 
in OCT compound (Miles Inc., West Haven, CT), and 5-/xm serial 
cryostat sections were prepared using a cryostat (Crycut 2000; 
Reichert  Jung, Nussloch, Germany).  Air-dried, acetone-fixed  frozen 
sections were  stained using  a  four-step immunohistochemical 
staining protocol as described previously (27). Briefly, cells were 
stained by sequential treatment  with (a) primary mAb (G28-5, 
mouse IgG1), (b)  biotin-conjugated  goat  anti-mouse  IgG,  (c) 
peroxidase-conjugated streptavidin, and (d) diaminobenzidine as 
chromogenic substrate. Finally, sections were counterstained with 
hematoxylin. Control stainings were performed by replacing the 
primary mAb with isotype-matched control reagents. The stained 
samples were evaluated  by four independent observers in a blinded 
fashion  using an Axioskop equipped with a MC100 camera system 
(Carl Zeiss, Inc., Thornwood,  NY). 
Results 
Endothelial Cells Express CD40.  To examine ifCD40/gp39 
binding may play a role  in  the interaction between  acti- 
vated T  cells and activated endothelial cells, we first exam- 
ined whether CD40 is expressed on endothelial cells. HUVEC 
of passage number 5 were stained with anti-CD40 mAb or 
sgp39 and examined by flow cytometry. As shown in Fig. 
1, CD40 is expressed by resting endothelial cells in culture. 
HAEC were also found to express CD40, as detected by FACS  | 
analysis (data not shown). To examine if this basal level of 
CD40 expression  can be altered by proinflammatory medi- 
ators,  HUVEC were incubated with TNF, IFN-'y, LPS, or 
IL-13. After 24 h, cells treated with the inflammatory  cytokines 
or LPS all showed slight but significant increases in expres- 
sion of CD40 (Fig. 2). Similar effects were seen after stimu- 
lation for 72 h (data not shown). These results suggest that 
the expression of CD40 by endothelial cells can be regulated 
by agents known to play a role in inflammation. Addition- 
ally, it was found that treatment of the cells with an anti- 
CD40 antibody for 24  h  substantially reduced the level of 
CD40 detected on the surface of the cells. In these experi- 
ments, the cells were incubated with the G28-5 antibody, 
and then subsequently stained with additional G28-5  anti- 
body. In this way, the total G28-5 bound to the cell surface 
is detected. The reduced level of CD40 detected is likely to 
be caused by internalization of the CD40.  This possibility 
is suggested by the observation that a G28-5 immunotoxin 
was capable of killing CD40-expressing B cell lymphomas, 
a process  dependent on internalization (15). 
Leukocyte Binding to Endothelial Cells Can Be Stimulated via 
CD40.  The ability of endothelial cells to respond to liga- 
Figure 1.  Expression  of CD40 
by HUVEC. HUVEC were as- 
sayed  by indirect  immunofluores- 
cence using (/1) sgp39, (B) nega- 
tive control fusion protein, (C) 
anti-CD40 mAb G28-5, or (D) 
isotype  matched  control  antibody. 
Filled  histograms  represent stain- 
ing with secondary  antibody  alone; 
solid  lines  represent staining  with 
the indicated protein. 
35  Hollenbaugh  et al. Figure 2.  Regulation  of  CD40 expression  on endothelial  cells  by inflam- 
matory mediators and anti-CD40 mAb. HUVEC were treated  with the 
indicated  agent  for 24 h, fixed,  and assayed  for CD40 expression  by ELISA 
as described  in Materials  and Methods. Value  is the mean of three points. 
tion of CD40 was tested using ~gp39, a soluble recombinant 
form of the CD40 ligand (24). HUVEC were incubated with 
the ~gp39 fusion protein for 4 h. The ability of the stimu- 
lated HUVEC to support the binding of HL60 cells or PMN 
isolated from peripheral blood was examined using a cell adhe- 
sion assay. Activation of HUVEC with soluble gp39 was found 
to induce adhesion of PMN in a concentration-dependent 
fashion (Fig. 3). Similar results were also found with the cell 
line HL-60 (data not shown). The ability of ~gp39 to induce 
the endothelial cells to mediate cell adhesion was blocked by 
anti-gp39 mAb (Fig. 3). Incubation of HUVEC with a con- 
trol fusion protein, ~CD72,  a putative ligand of CD5, did 
not induce the endothelial cells to mediate cell adhesion (data 
not shown). Binding of PMN or HL-60 cells to endothelial 
cells was confirmed visually in each experiment. 
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Figure  3.  Adhesion  of PMN to sgp39-stimulated endothelial cells. 
HUVEC were treated with sgp39 for 4 h in the presence (solid triangle) 
or absence  (open  squares)  of  an anti-gp39-blocking  mAb, 39-1.106 (5/zg/ml). 
The cells were then tested  for the ability  to support adhesion  of fluores- 
cently labeled PMN. Value is the mean of three points, and error bars 
represent the standard deviation. 
CD40 Stimulation  Leads to E-Selectin Expression.  To de- 
termine  the  molecular  basis  of the  gp39-induced  leuko- 
cyte-HUVEC cell adhesion, we examined the levels of  E-sdec- 
tin expression after sgp39 stimulation. As shown in Fig. 4, 
incubation of HUVEC with sgp39 resulted in the expres- 
sion of significant levels of E-selectin.  The ability of sgp39 
to induce E-selectin expression was completely inhibited by 
the addition of anti-gp39 mAb. To investigate whether other 
types of endothelial cells were able to respond to ligation of 
CD40, healthy HAEC were also tested for the ability to ex- 
press  E-selectin  after  stimulation  with  sgp39.  Like  the 
HUVEC,  the  HAEC  expressed  E-selectin  in  response  to 
~gp39 in a concentration-dependent manner. This induction 
was inhibited by a blocking antibody to gp39 (Fig. 4 B). In- 
cubation of HUVEC with the control fusion protein sCD72 
did not drive E-selectin expression  (data not shown).  The 
ability of ~gp39 to induce E-selectin  expression  was also in- 
hibited by CD40Ig, a fusion protein consisting of the extra- 
cellular domain of CD40 fused to human Ig (24)  and the 
anti-CD40 antibody G28-5.  The G28-5  antibody was un- 
able to stimulate E-selectin expression. These results are similar 
to that seen by Lederman et al. (28), where anti-CD40 was 
used to inhibit the ability of gp39-expressing cells to stimu- 
late CD23  expression  by B cells. Combinations of subop- 
timal levels of TNF and ~gp39 were additive and not syner- 
gistic in E-selectin  induction (data not shown). 
Stimulation  through CD40 Leads to Expression of lCAM-I 
but Not  VCAM-1.  To investigate the role of gp39 in the 
induction of expression of other cell adhesion molecules,  the 
expression of ICAM-1 and VCAM-1 was measured after 24 h 
of stimulation with ~gp39 (Fig.  5).  Expression of ICAM-1 
was induced by sgp39 in a concentration-dependent manner. 
This induction was inhibited by the F(ab')2 fragment of an 
anti-gp39 antibody, 39-1.106. In contrast, VCAM-1 was not 
induced by sgp39.  However, the induction of VCAM-1 by 
low levels of TNF was augmented by sgp39 in a concentra- 
tion-dependent manner. This increase was blocked by the anti- 
gp39  mAb F(ab')2. 
Expression of CD40 by Endothelial Cells in Tissue Sections.  We 
examined the expression  of CD40 in vivo by immunohisto- 
chemistry. In healthy human skin, little if any CD40 was 
detected on dermal endothelial cells (Fig. 6 A). By contrast, 
a marked upregulation of endothelial cell CD40 expression 
was a constant feature of inflammatory skin disease, such as 
allergic  contact dermatitis and psoriasis  (Fig.  6, B and C). 
Furthermore, in psoriasis,  an enhanced expression  of CD40 
was detected on keratinocytes in the basal and suprabasal layers, 
as well as on the dermal mononuclear infiltrate (Fig.  6,/3 
and C). The detection of CD40 on HUVEC in culture, but 
not in healthy skin, may be a reflection of the partially acti- 
vated state of the HUVEC under the culture conditions used. 
This has been observed previously,  for example,  in the ex- 
pression of CD44, where slightly different conditions used 
in different laboratories yielded differing levels of expression. 
The ability to further increase CD40 expression indicates the 
ability of the cells to respond despite the "inflamed" charac- 
teristics  of the cultured cells (29,  30). 
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Figure  4.  E-selectin expression on endothelial cells 
induced by ~gp39. (A) HUVEC and (B) HAEC were 
treated with sgp39 for 4 h in the presence (solid triangles) 
or absence (open squares) of an anti-gp39-blocking mAb, 
39-1.106 (5 #g/ml), then tested  for the expression  of 
E-selectin by ELISA. Values are the mean of three points, 
and error bars represent  the SD. Error bars are absent 
when the bar is smaller  than the graph  symbol. 
Discussion 
CD40 is known to be a signaling receptor for a range of 
cell types of the immune system. Here we report the expres- 
sion of functional CD40 by endothelial cells, the increase  of 
CD40  expression in inflammatory  skin disease,  and a pos- 
sible role of a CD40-gp39  interaction in the regulation of 
cell adhesion molecules. Endothelial cells are known to play 
a role in the initiation of inflammation. Inflammatory medi- 
ators induce endothelial cell expression of adhesion molecules 
to initiate the recruitment of leukocytes to the inflamed area. 
In this process, the leukocytes are stimulated by proteins ex- 
pressed by, or presented on, the activated endothelium,  in- 
cluding proteoglycan bound cytokines  and surface  proteins 
such as the integrin ligands ICAM-1  or VCAM-1  (31-34). 
The endothelium is also stimulated by the migrating leuko- 
cytes, thus providing a mechanism for amplification and ex- 
tension of the inflammatory response. In addition to playing 
a key role in the recruitment of leukocytes during inflamma- 
tion,  endothelial cells may express MHC class  I and MHC 
class II, thus allowing the endothelial cell to function directly 
as an APC (35). The finding reported here,  that endothelial 
cells express CD40, a receptor present on monocytes, B cells, 
and dendritic cells,  strengthens the notion of these cells as 
APC and provides a mechanism for contact-dependent  sig- 
naling of the endothelial  cell by the migrating  leukocyte. 
We have demonstrated that signaling through CD40 in- 
duces the expression of adhesion molecules on the endothelial 
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Figure  5.  ICAM-1 and VCAM-1 expression  on en- 
dothelial cells induced by ~gp39 and TNF-o~. HUVEC 
were treated with ~gp39 for 24 h in the presence (solid 
squares) or absence  (open squares) of an anti-gp39-blocking 
mAb, 39-1.106 (5 #g/ml), and in the presence  or ab- 
sence of TNF-t~,  and then tested for the expression  of 
ICAM-1 or VCAM-1 by ELISA. (.4) ICAM-1 expres- 
sion induced by sgp39. (B) ICAM-1 expression induced 
by sgp39 in the presence  of 0.01  ng/ml TNF-ol.  (C) 
VCAM-1 expression induced by sgp39. (D) VCAM-1 
expression  induced  by ~gp39 in  the  presence  of 0.1 
ng/ml TNF-c~. The expression levels measured for un- 
stimulated cells are shown in A  and C (open circle). The 
expression levels  in the presence  of TNF-ct  alone are 
shown in B  and D  (open circle). Value is the mean of 
three points, and error bars represent the standard devi- 
ation. Error bars are absent when the bar is smaller than 
the graph  symbol. Figure  6.  Upregulation  of 
CD40 on dermal endothelial cells 
in inflammatory  skin diseases.  (.4) 
Healthy  skin: faint CD40 staining 
on dermal endothelial  cells  (arrow- 
heads). (13) Psoriasis: upregulation 
of CD40 on dermal endothelial 
cells (arrowheads)  and on perivas- 
cular mononuclear cells (arrow- 
heads), as well as on keratinocytes 
in  the  epidermis (arrows). (C) 
Psoriasis: marked CD40 expres- 
sion on dermal endothelial cells 
(arrowheads) and on perivascular 
mononuclear  cells (arrowheads) 
Bars: (.4  and C)  100 /~m; (B) 
400/zm. 
cell,  thus providing  a possible mechanism  for the reported 
ability of primed CD4 § T  cells to stimulate endothelial cell 
adhesion molecule expression (36). This is similar to the in- 
duction  of adhesion  in  CD40-stimulated  B  cells,  where a 
homotypic aggregation occurs in culture in response to anti- 
CD40 by the induction of ICAM-1 as well as the activation 
of the CD18 integrins (37).  In the case of endothelial cell-ac- 
tivated T cell interactions, it might be expected that the inte- 
grins would be present in a high-avidity form, and the in- 
duction  of ICAM-1  allows  for  a  high-avidity  heterotypic 
interaction. These interactions have been shown to be required 
for intercellular  signaling and diapedesis (38).  For example, 
the induction of proliferation of B cells in response to in vitro- 
activated T  cells  can be blocked by anti-CD18  mAb  (39). 
The tight adhesion provided by the integrin-integrin  ligand 
may allow contact for T cell-endothelial cell signaling,  leading 
to  extension  or  amplification  of the  inflammation  and/or 
migration of the bound T cell. The differential  effect of CD40 
signaling on the expression of ICAM-1 versus VCAM-1 also 
suggests that the gp39-CD40 system may contribute to the 
specificity of the cell populations  that  are recruited by the 
endothelium by altering  the pattern  of adhesion molecules 
that  are expressed. Evaluation of the role of these adhesion 
molecules for the interaction of endothelial cells with other 
gp39-expressing cell types awaits identification of the require- 
ments  of activation  for gp39 expression and nature  of the 
coexpressed adhesion  molecules. 
The ability of gp39-expressing cells to stimulate endothelial 
cells has implications in several disease states.  Here we report 
that gp39 induces endothelial cell expression of adhesion pro- 
teins involved in the initiation and maintenance of an inflam- 
matory response. In a normal inflammatory response, a pro- 
cess to limit these mechanisms and to allow for a resolution 
of the inflammation  is expected.  However, gp39 may play 
a role in inflammatory disease states,  where aberrant expres- 
sion  may  maintain  activation.  Our  finding  that  CD40  is 
expressed on endothelial  cells  in inflammatory  skin disease 
demonstrates  an  in  vivo  association  of this  receptor  with 
inflammation.  Functional CD40-gp39 interaction may play 
a role in other  forms of inflammation  and disease,  such as 
chronic graft rejection,  where the stimulation of the endothelial 
cells by host lymphocytes induces mononuclear cell infiltrate, 
vascular smooth muscle cell activation and proliferation, and 
ECM deposition. In acute rejection, the allogeneic stimula- 
tion of host T  cells would be expected to induce expression 
of gp39 along with other stimulatory proteins, inducing ex- 
pression of adhesion molecules on the graft endothelium. In- 
deed, expression of VCAM-1 and ICAM-1 are indicative of 
rejection and precede leukocyte infiltration (4042). The pres- 
ence of a population of T cells that are responsive to endothelial 
cells has also been indicated in autoimmune  states.  For ex- 
ample, induction of autoimmunity in insulin-dependent dia- 
betes mellitus in rats correlates with the presence of T  cells 
that are able to activate the endothelium (43). This suggests 
the importance of this interaction in vivo and the potential 
role of CD40-gp39  interactions  in  autoimmunity. 
In summary,  we have identified the expression of CD40 
by activated endothelial cells and have demonstrated the ability 
to induce the expression of adhesion proteins  through  this 
receptor. The induction of CD40 in allergic contact derma- 
titis  and psoriasis  suggests an association of CD40 expres- 
sion with inflammatory disease that is supported by the ability 
of inflammatory mediators to upregulate expression in vitro. 
The  consideration  of endothelial  cells as APC is also  sup- 
ported by the expression of functional CD40; this is the sub- 
ject of further  study. 
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